Brief: Lilly's Foundayo Delivers Superior A1C Control & Weight Loss In Three Type 2 Diabetes Trials

Eli Lilly and Co

08/06/2026 19:34

June 9 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S ORAL GLP-1 FOUNDAYO (ORFORGLIPRON) DELIVERED SUPERIOR A1C CONTROL AND WEIGHT LOSS IN THREE PIVOTAL TYPE 2 DIABETES TRIALS
ELI LILLY - TO SUBMIT FOUNDAYO FOR TYPE 2 DIABETES TO U.S. FDA BY END OF Q2
ELI LILLY - FOUNDAYO 17.2 MG LOWERS A1C BY 2.2% AT 52 WEEKS VERSUS 1.4% WITH ORAL SEMAGLUTIDE 14 MG
ELI LILLY - FOUNDAYO 17.2 MG ACHIEVES 57.1% GREATER A1C REDUCTION AND 73.6% GREATER WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE 14 MG
ELI LILLY - FOUNDAYO MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS
ELI LILLY - IN ACHIEVE-3 TRIAL, FOUNDAYO OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY AND ALL KEY SECONDARY ENDPOINTS
ELI LILLY: OVERALL SAFETY AND TOLERABILITY PROFILE OF FOUNDAYO, INCLUDING TREATMENT DISCONTINUATION RATES, WAS CONSISTENT WITH PREVIOUS STUDIES
Source text: ID:nPn3vCKya
Further company coverage: LLY.N

 ((Reuters.Briefs@thomsonreuters.com;;))